| Date | Title | Description |
| 03.12.2024 | Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program | Expanded agreement with Dana-Farber Cancer Institute enables further acceleration of Red Queen program in SARS-CoV-2 and advanced delivery options
Red Queen also has filed patents covering its novel pan-influenza treatment, for which the co... |
| 03.12.2024 | Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program | Expanded agreement with Dana-Farber Cancer Institute enables further acceleration of Red Queen program in SARS-CoV-2 and advanced delivery options
Red Queen also has filed patents covering its novel pan-influenza treatment, for which the co... |
| 06.08.2024 | Apple Tree Partners Launches Red Queen Therapeutics to Bring Potentially Lifesaving Treatments to People at Greatest Risk from Viral Infections | Red Queen uses a novel antiviral platform to create pan-variant treatments for coronaviruses, influenza, RSV, and other serious viral diseases, with recent clinical validation in COVID-19 patients
Company operates with $55 million Series A ... |
| 06.08.2024 | Red Queen Therapeutics Raises USD55M in Series A Funding | Red Queen Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised USD55M in Series A funding.
Apple Tree Partners made the investment.
The company intends to use the funds to expand operations and its development ef... |
| 06.08.2024 | Apple Tree Partners Launches Red Queen Therapeutics to Bring Potentially Lifesaving Treatments to People at Greatest Risk from Viral Infections | Red Queen uses a novel antiviral platform to create pan-variant treatments for coronaviruses, influenza, RSV, and other serious viral diseases, with recent clinical validation in COVID-19 patients
Company operates with $55 million Series A ... |
| - | Red Queen Therapeutics | “Staying ahead of viral threats with new innovations in antiviral therapy” |
